Connect to Hemophilia A Treatment Dosing Convenience


Helixate FS: Purification and virus inactivation

Mix2VialTM: A simple way to mix Helixate FS for hemophilia A patients

Helixate FS is designed with a patient’s daily needs in mind. Mix2Vial is one design feature that may shorten preparation and reconstitution time by providing a quicker way to reconstitute Helixate FS.

Reconstitution made easy

  • The Mix2Vial needle-free transfer device allows for reconstitution with:
    • Less risk of needle-stick injuries
    • Less time to prepare product
  • Simple process encourages self-infusion
  • Built-in filter
  • For use with all BD Luer-Lok™ syringes

Other patient-friendly features of Helixate FS

In addition to Mix2Vial, Helixate FS has many other benefits designed to make treatment more convenient for hemophilia A patients. In particular, the 3000 IU/5 mL dose may shorten preparation time. For smaller doses, Helixate FS has one of the smallest diluent sizes available — 2.5 mL.

  • Dosing for every patient
    • One of the smallest diluent sizes available for 250 IU, 500 IU, and 1000 IU doses (2.5 mL)
    • 2000 IU/5.0 mL dose
  • High-concentration dose
    • 3000 IU/5.0 ml dose allows infusion of higher doses without using multiple vials
  • Room temperature storage (up to 25°C [77°F])
    • You can store Helixate FS for up to 12 months at room temperature
    • Storage is easier both at home and on-the-go for hemophilia A patients
  • Color-coded, peel-off labels
    • Special labels make identification and record-keeping simple
    • Log infusions and report information to HTCs

Next: Monitoring Therapy: HeliTraxSM »

Important Safety Information

Helixate® FS, Antihemophilic Factor (Recombinant), is a recombinant factor VIII treatment indicated for the control and prevention of bleeding episodes and peri-operative management in adults and children (0-16 years) with hemophilia A. Helixate® FS is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A with no preexisting joint damage.

The most serious adverse reactions are systemic hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to antihemophilic factor. The most common adverse reactions observed in clinical trials were inhibitor formation in previously untreated or minimally treated patients, skin-associated hypersensitivity reactions, infusion site reactions, and central venous access device (CVAD) line-associated infections.

Helixate® FS is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including mouse or hamster proteins.

Please see the full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.